Drugs / ZYGK1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01472809 | Dec 2011 → Dec 2012 | diabetes mellitus | Zydus Lifesciences Limited | Suspended | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2011-07-19 | Zydus Lifesciences Limited | Regulatory Zydus Cadila Q1 Net profit reaches Rs. 230 crore zyduslife.com ↗
During the quarter, the group received an approval from the USFDA for its IND application of ZYGK1, a potent and orally administered small molecule glucokinase activator. |
| 2011-04-07 | Zydus Lifesciences Limited | Regulatory Zydus IND application of ZYGK1 for treating diabetes receives USFDA approval zyduslife.com ↗
Zydus Cadila, a global healthcare provider and one of India’s leading healthcare companies announced that it has received an approval from the USFDA for its IND application of ZYGK1. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2011-07-19 | Zydus Lifesciences Limited | Zydus Cadila Q1 Net profit reaches Rs. 230 crore zyduslife.com ↗ |
| 2011-04-07 | Zydus Lifesciences Limited | Zydus IND application of ZYGK1 for treating diabetes receives USFDA approval zyduslife.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZYGK1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01472809 ↗ |
| Action | Activate | “a Novel Glucokinase Activator” NCT01472809 ↗ |
| Route | Oral | “Following Oral Administration” NCT01472809 ↗ |